Butterfly Network CEO Pitches Chip Licensing as Potential Revenue Juggernaut; Core Ultrasound Business Still Unproven

What happened

Butterfly Network (BFLY) shares are in focus after CEO Joe DeVivo suggested its semiconductor licensing business could eventually exceed the company's core handheld ultrasound device revenue. The comment, made during a UBS MedTech discussion, highlights a strategic expansion beyond selling iQ3 probes to monetizing its Ultrasound-on-Chip technology through third-party licenses. This comes as the company continues to execute on its existing enterprise software push, with 2024 revenue of $82.1 million and a net loss of $72.5 million, and cash of $152 million as of Q2 2025. While the chip licensing opportunity remains largely unproven and lacks financial details, it adds a potentially high-margin revenue stream to Butterfly's portfolio. Investors will likely watch for concrete licensing agreements and revenue recognition before giving full credit to this new narrative.

Implication

Investors should treat the chip licensing announcement as a longer-term call option on Butterfly's semiconductor IP, not a near-term revenue driver. The core thesis remains unchanged: the company needs to demonstrate sustainable growth in device sales, higher software attach, and meaningful gross margin expansion to justify its valuation. While licensing could theoretically provide a capital-light, high-margin revenue stream, the lack of disclosed terms, partners, or timeline makes it speculative. Until Butterfly secures meaningful licensing agreements with clear economics, it is prudent to maintain a HOLD rating and monitor for execution on both the core business and the new chip initiative. Positive signals would include a named licensee with upfront payments or royalties, and evidence that the chip business does not distract management from the primary ultrasound commercialization.

Thesis delta

No change to our HOLD rating, but the chip licensing commentary introduces a new avenue for value creation that we will track closely. The potential for chip revenue to dwarf the device business, if realized, could materially improve the company's long-term margin profile and reduce dependence on competitive handheld markets. However, until there is evidence of actual licensing deals and revenue contribution, we do not adjust our valuation or risk assessment.